Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gut microbiome and metabolome dynamics as predictors of clinical outcomes in hematopoietic stem cell transplantation

ABSTRACT: Hematopoietic stem cell transplantation (HSCT) induces significant alterations in the gut microbiome and metabolome, which influence transplant-related complications and surviv-al. This study longitudinally analyzed gut microbiota and metabolites at pre- (T1), peri- (T2), and post-transplant (T3) stages to identify key determinants of clinical outcomes. Lower microbiome diversity at T1 and T3 correlated with graft-versus-host disease (GVHD), progressive disease (PD), and reduced overall survival (OS). Short-chain fatty acids (SCFAs), particularly acetate, declined over time, with reductions at T2-T1 linked to GVHD, diarrhea, PD, and lower OS. Specific perspective metabolites (SPMs) such as elevated uric acid at T2 were associated with GVHD, while reduced 1-phenylethylamine correlated with diarrhea. Patients with enriched beneficial taxa (e.g., Lachnospiraceae, Ruminococcaceae) exhibited improved OS. These findings highlight the gut microbiome-metabolome axis as a predictive marker for HSCT outcomes. Identifying microbial and metabolic signatures may provide novel diagnostic and therapeutic targets for mitigating HSCT-related complications, enhancing patient prognosis.

INSTRUMENT(S): Gas Chromatography MS -

PROVIDER: MTBLS12365 | MetaboLights | 2025-07-30

REPOSITORIES: MetaboLights

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	H02_1.cdf	Other
	H02_2.cdf	Other
	H02_3.cdf	Other
	H03_1.cdf	Other
	H03_2.cdf	Other

Items per page:

1 - 5 of 186

Similar Datasets

PROTEOMIC ANALYSIS OF MACHINE PERFUSION SOLUTION FROM BRAIN DEAD DONOR KIDNEYS REVEALS THAT COMPLEMENT ACTIVATION IS ASSOCIATED WITH 1-YEAR OUTCOME

Project description:Current strategies to assess donor kidney quality are based on clinical scores or require biopsies for histological assessment. Non-invasive strategies to identify and predict graft outcome at an early stage are therefore needed. Our aim was to evaluate the secretome in non-oxygenated hypothermic machine perfusion (HMP) perfusate of donation after brain death (DBD) kidneys by comparing proteomic profiles of good outcome (GO) and ¬suboptimal outcome (SO) 1-year post transplantation. Samples taken 15 minutes after start of HMP (T1) and before termination of HMP (T2) were analysed using liquid chromatography tandem mass spectrometry (LC MS/MS). Hierarchical clustering of the 100 most abundant proteins showed discrimination between grafts with a GO and SO at T1. Upregulated expression of proteins involved in classical complement activation at both T1 and T2, and downregulated expression lipid metabolism at T1 and of cytoskeletal proteins at T2 in GO vs. SO was observed. ATP-citrate synthase and fatty acid binding protein 5 (T1) and immunoglobulin heavy variable 2-26 and Desmoplakin (T2) showed 91% and 86% predictive values respectively for transplant outcome. This study shows that the secretome of DBD kidneys can distinguish between outcome 1-year post transplantation. Furthermore, it provides insights into mechanisms that could play a role in post- transplant outcomes.

2022-08-12 | PXD027127 | Pride

Transplant immunosuppressant therapies induce unique functional changes in and re-shape gut immune homeostasis

Project description:Current immunosuppressants effectively suppress adaptive and innate immune responses, but their broad, antigen-non-specific effects often result in significant complications. Here we investigated understudied immunosuppressant effects of four major immunosuppressant classes including tacrolimus, prednisone, mycophenolate mofetil (MMF), and Fingolimod (FTY), on the gut microbiome, metabolic pathways, lymphoid architecture and lymphocyte trafficking. Despite their distinct mechanisms of action, all drugs induced progressive alterations from moderate early changes to substantial alterations in the gut microbiome composition and metabolic pathways with prolonged treatment, converging to a shared dysbiotic state. This was accompanied by significant metabolic alterations and distinct phases of intestinal transcriptional responses. Time-dependent changes in lymph node (LN) reorganization and cellular composition were also observed, showing compartmentalized immune regulation in mesenteric and peripheral lymphoid tissues. Together, these findings highlight the underappreciated complexity and temporal dynamics of immunosuppressant effect, linking drug-induced changes in gut microbiome and compartmentalized immune regulation in lymphoid tissues. Notably, MMF and FTY demonstrated most robust immunomodulatory properties, and were able to suppress alloantigen-induced inflammation through mediating regulatory T cells and LN remodeling. Understanding these relationships provides new opportunities for refining immunosuppressive strategies to mitigate treatment-related complications in transplant patients, ultimately improving long-term organ transplant outcomes.

2025-06-24 | GSE288074 | GEO

Human marginal zone B cell development from early T2 progenitors [MZBTraj]

Project description:B cells emerge from the bone marrow as transitional (TS) B cells that differentiate through T1, T2 and T3 stages to become naïve B cells. We have identified a bifurcation of human B cell maturation from the T1 stage forming IgMhi and IgMlo developmental trajectories. IgMhi T2 cells have higher expression of a4b7 integrin and lower expression of IL4 receptor (IL4R) compared to the IgMlo branch and are selectively recruited into gut-associated lymphoid tissue. IgMhi T2 cells also share transcriptomic features with marginal zone B cells (MZB). Lineage progression from T1 cells to MZB via an IgMhi trajectory is identified by pseudotime analysis of scRNA-sequencing data. Reduced frequency of IgMhi gut homing T2 cells is observed in severe SLE and is associated with reduction of MZB and their putative IgMhi precursors. The collapse of the gut-associated MZB maturational axis in severe SLE affirms its existence in health.

2021-01-31 | GSE163602 | GEO

Human marginal zone B cell development from early T2 progenitors [Pooled]

2021-01-31 | GSE163493 | GEO

Gene expression profiling of sequential metastatic biopsies for biomarker discovery in breast cancer

Project description:The feasibility of longitudinal metastatic biopsies for gene expression profiling in breast cancer is unexplored. Dynamic changes in gene expression can potentially predict efficacy of targeted cancer drugs. Patients enrolled in a phase III trial of metastatic breast cancer with sunitinib combined with docetaxel (SU+DOC) versus docetaxel alone (DOC) were offered to participate in a translational substudy comprising longitudinal fine needle aspiration biopsies (FNAB) and positron emission imaging before (T1) and two weeks after start of treatment (T2). Aspirated tumor material was used for microarray analysis, and treatment-induced changes (T2 versus T1) in gene expression and standardized uptake values were investigated. Twenty-one patients were included in the docetaxel ± sunitinib trial at Karolinska and 18 of them agreed to participate in the substudy. Of the 18 women enrolled, 8 were randomly assigned to SU+DOC and 10 to DOC. Metastatic FNAB were carried out in 17 of the 18 patients at both time points with no complications reported. Representative tumor material, sufficient for RNA extraction was obtained in 15 patients at T1 and 14 patients at T2. Matched samples both at T1 and T2 were obtained for 14 subjects, 7 in each arm. The main objective was to determine whether gene expression profiling is feasible using sequential, intra-patient FNAB. Secondary objectives were to identify potential biomarkers of early response by gene expression and/or functional imaging and to explore drug action in vivo by changes in gene expression.

2015-04-14 | GSE54323 | GEO

Effect of intestinal microbiome diversity on the efficacy and survival of chemotherapy for advanced non-small cell lung cancer

Project description:Interventions: Response Group:none;None Response Group:Nil Primary outcome(s): CR;PR;SD;PD;PFS;OS;Gut microbiome;Fecal metabolomics;Immune factor Study Design: Factorial

| 2689133 | ecrin-mdr-crc

Gut microbiome dysregulation is associated with elevated toxic bile acids in Parkinson’s disease

Project description:The gut microbiome can impact brain health and is altered in Parkinson’s disease (PD) patients. The vermiform appendix is a lymphoid tissue implicated in the storage and regulation of the gut microbiome. Here, we investigate changes in the functional microbiome in the appendix of PD patients relative to controls by metatranscriptomic analysis. In the PD appendix, we find microbial dysbiosis affecting lipid metabolism, particularly an upregulation of bacteria responsible for secondary bile acid synthesis. Likewise, proteomic and transcript analysis in the PD gut corroborates a disruption in cholesterol homeostasis and lipid catabolism. Bile acid analysis in the PD appendix reveals an increase in the microbially-derived, toxic secondary bile acids deoxycholic acid (DCA) and lithocholic acid (LCA). Synucleinopathy in mice induces similar microbiome alterations to those of PD patients and heightens microbial changes to gut inflammation. As observed in PD, the mouse model of synucleinopathy has elevated DCA and LCA. Raised levels of DCA and LCA can lead to liver injury, and an analysis of blood markers of liver dysfunction shows evidence of biliary abnormalities in PD patients, including elevated alkaline phosphatase and bilirubin. Increased bilirubin levels are also evident before PD diagnosis, in individuals at-risk of developing PD. In sum, microbially-derived toxic bile acids are heightened in PD and biliary changes may even precede the onset of overt motor symptoms.

2021-08-01 | GSE156647 | GEO

The Gut Microbiome of renal transplant recipients Ã¢Â€Â“ Cross-sectional

Project description:TransplantLines is designed as a single-center, prospective cohort study and biobank including all different types of solid organ transplant recipients as well as living organ donors. In the TransplantLines gut microbiome study the gut microbiome of solid organ transplant recipients is characterized and linked to clinical phenotypes. This batch contains the cross-sectional data from renal transplant recipients is.

| EGAS00001006257 | EGA

The Gut Microbiome of liver transplant recipients Ã¢Â€Â“ Cross-sectional + Longitudinal (renal and liver)

| EGAS00001006258 | EGA

Effects of intestinal microbiome diversity on the efficacy and survival of chemotherapy combined with immunotherapy and immunotherapy in advanced non-small cell lung cancer

Project description:Interventions: Group 1:Chemotherapy combined with immunotherapy;Group 2:Immunotherapy Primary outcome(s): CR;PR;SD;PD;PFS;OS;Gut microbiome;Fecal metabolomics;Immune factor Study Design: Non randomized control

| 2689155 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data